ArticleFrontiers in nutrition2025
Global, regional, and national disease burden of lymphoma and leukemia attributable to high body mass index: from 1990 to 2021.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymphoma and leukemia were the most common hematological malignancies worldwide. Metabolic factors, such as high body mass index, are potential risk factors for various cancers. This study aimed to analyze the disease burden and the incidence trend of non-Hodgkin and acute leukemia attributable to high BMI around the world from 1990 to 2021. Methods: Using the data released by the Global Burden of Disease study 2021 (GBD 2021), we analyze the disease burden of non-Hodgkin lymphoma and acute leukemia attributable to high BMI from 1990 to 2021 via morbidity, death, disability-adjusted life years (DALY), and predict the obesity-related death trend in for the next 20 years (2022-2046). Results: The death cases of non-Hodgkin lymphoma, acute myeloid leukemia and acute lymphoid leukemia attributable to BMI in 2021 were 12,796, 11,947 and 4,116 respectively, with an increase of 153,9, 169.9, and 92.6% compared with 1990. The age-standardized mortality rate (ASMR) in 2021 attributable to BMI grew from 0.13/100,00, 0.11/100,000 and 0.05/100,000 in 1990 to 0.15/100,00, 0.14/100,00 and 0.05/100,000 in 2021. In 2021, the number of deaths cases and DALYs case were generally higher in male population and older population. The prediction of the neural network model showed that the incidence and death of the disease would remain high and rise in the next 25 years. Conclusion: High BMI has become a risk factor for leukemia and lymphoma and threatened public health globally. We should pay more attention to the role of metabolic factors and made more proactive and effective strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.